Introduction:

The new coronavirus has genetic material. This allows a receptor to transform into the polybasic site of action and it is capable of infecting through multiple entry receptors and highlighting spike-like (S) proteins. The spike protein is a viral fusion protein of Covid-19, which is why in the therapeutic search the following questions are established, will antibody hybridization succeed in winning the war against the Covid-19 pandemic? Or can antibody-rich plasma keep people out of intensive care units? These questions are that current studies do not establish the true utility of immune therapy.

Objective:

To settle the usefulness of hybrid antibodies to the current Covid-19 pandemic and other coronaviruses.

Methods:

A bibliographic review was developed from the existing evidence about the panorama of proteomics in the study of the immune system to fight infections. A time frame was used between 1999 and 2020. A total of 37 documents, in English or Spanish, that comply with the inclusion protocols were selected; MeSH terms were used in the search. Observational or analytical studies were chosen; experimental, case report dating biochemical, biological, pathological and clinical aspects of the immune system as a therapeutic target in the current pandemic. The documentary analysis was carried out by the Health Research Group of the Universidad del Cauca-Popayán, with the support and direction of the University of Houston, Texas (USA), with the support of faculty from NASA Human Research Program.

Results:

The positive response to control this pandemic is based on preventive care and possible innovative therapies for the new coronaviruses that manage to be transmitted from animals to humans.

Conclusions:

The possible use of hybrid single domain antibodies to stop new viral infections is highlighted.

        · resumen en Español     · texto en Español     · Español ( pdf )